Terms: = Leukemia AND KAT6B, DKFZp313G1618, 23522, MYST4, ENSG00000156650, Q8WYB5, querkopf, qkf, MOZ2, MORF, KIAA0383, FLJ90335
26 results:
1. MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins.
Komata Y; Kanai A; Maeda T; Inaba T; Yokoyama A
Nat Commun; 2023 Apr; 14(1):1979. PubMed ID: 37031220
[TBL] [Abstract] [Full Text] [Related]
2. morf and MOZ acetyltransferases target unmethylated CpG islands through the winged helix domain.
Becht DC; Klein BJ; Kanai A; Jang SM; Cox KL; Zhou BR; Phanor SK; Zhang Y; Chen RW; Ebmeier CC; Lachance C; Galloy M; Fradet-Turcotte A; Bulyk ML; Bai Y; Poirier MG; Côté J; Yokoyama A; Kutateladze TG
Nat Commun; 2023 Feb; 14(1):697. PubMed ID: 36754959
[TBL] [Abstract] [Full Text] [Related]
3. Role of the MOZ/MLL-mediated transcriptional activation system for self-renewal in normal hematopoiesis and leukemogenesis.
Yokoyama A
FEBS J; 2022 Dec; 289(24):7987-8002. PubMed ID: 34482632
[TBL] [Abstract] [Full Text] [Related]
4. The key roles of the lysine acetyltransferases KAT6A and kat6b in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract] [Full Text] [Related]
5. Recognition of Histone H3K14 Acylation by morf.
Klein BJ; Simithy J; Wang X; Ahn J; Andrews FH; Zhang Y; Côté J; Shi X; Garcia BA; Kutateladze TG
Structure; 2017 Apr; 25(4):650-654.e2. PubMed ID: 28286003
[TBL] [Abstract] [Full Text] [Related]
6. Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics.
Matondo M; Marcellin M; Chaoui K; Bousquet-Dubouch MP; Gonzalez-de-Peredo A; Monsarrat B; Burlet-Schiltz O
Proteomics; 2017 Apr; 17(7):. PubMed ID: 27709814
[TBL] [Abstract] [Full Text] [Related]
7. MOZ and morf acetyltransferases: Molecular interaction, animal development and human disease.
Yang XJ
Biochim Biophys Acta; 2015 Aug; 1853(8):1818-26. PubMed ID: 25920810
[TBL] [Abstract] [Full Text] [Related]
8. The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors.
You L; Yan K; Zou J; Zhao H; Bertos NR; Park M; Wang E; Yang XJ
PLoS Genet; 2015 Mar; 11(3):e1005034. PubMed ID: 25757017
[TBL] [Abstract] [Full Text] [Related]
9. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract] [Full Text] [Related]
10. Tandem PHD fingers of morf/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin.
Ali M; Yan K; Lalonde ME; Degerny C; Rothbart SB; Strahl BD; Côté J; Yang XJ; Kutateladze TG
J Mol Biol; 2012 Dec; 424(5):328-38. PubMed ID: 23063713
[TBL] [Abstract] [Full Text] [Related]
11. Disruption of the histone acetyltransferase myst4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice.
Kraft M; Cirstea IC; Voss AK; Thomas T; Goehring I; Sheikh BN; Gordon L; Scott H; Smyth GK; Ahmadian MR; Trautmann U; Zenker M; Tartaglia M; Ekici A; Reis A; Dörr HG; Rauch A; Thiel CT
J Clin Invest; 2011 Sep; 121(9):3479-91. PubMed ID: 21804188
[TBL] [Abstract] [Full Text] [Related]
12. Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase UBC9 and likely interferes with polySUMOylation.
Yousef AF; Fonseca GJ; Pelka P; Ablack JN; Walsh C; Dick FA; Bazett-Jones DP; Shaw GS; Mymryk JS
Oncogene; 2010 Aug; 29(33):4693-704. PubMed ID: 20543865
[TBL] [Abstract] [Full Text] [Related]
13. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases.
Murati A; Gervais C; Carbuccia N; Finetti P; Cervera N; Adélaïde J; Struski S; Lippert E; Mugneret F; Tigaud I; Penther D; Bastard C; Poppe B; Speleman F; Baranger L; Luquet I; Cornillet-Lefebvre P; Nadal N; Nguyen-Khac F; Pérot C; Olschwang S; Bertucci F; Chaffanet M; Lessard M; Mozziconacci MJ; Birnbaum D;
Leukemia; 2009 Jan; 23(1):85-94. PubMed ID: 18818702
[TBL] [Abstract] [Full Text] [Related]
14. Molecular architecture of quartet MOZ/morf histone acetyltransferase complexes.
Ullah M; Pelletier N; Xiao L; Zhao SP; Wang K; Degerny C; Tahmasebi S; Cayrou C; Doyon Y; Goh SL; Champagne N; Côté J; Yang XJ
Mol Cell Biol; 2008 Nov; 28(22):6828-43. PubMed ID: 18794358
[TBL] [Abstract] [Full Text] [Related]
15. MOZ and morf, two large MYSTic HATs in normal and cancer stem cells.
Yang XJ; Ullah M
Oncogene; 2007 Aug; 26(37):5408-19. PubMed ID: 17694082
[TBL] [Abstract] [Full Text] [Related]
16. MOZ fusion proteins in acute myeloid leukaemia.
Troke PJ; Kindle KB; Collins HM; Heery DM
Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
[TBL] [Abstract] [Full Text] [Related]
17. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
Kindle KB; Troke PJ; Collins HM; Matsuda S; Bossi D; Bellodi C; Kalkhoven E; Salomoni P; Pelicci PG; Minucci S; Heery DM
Mol Cell Biol; 2005 Feb; 25(3):988-1002. PubMed ID: 15657427
[TBL] [Abstract] [Full Text] [Related]
18. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase morf.
Moore SD; Herrick SR; Ince TA; Kleinman MS; Dal Cin P; Morton CC; Quade BJ
Cancer Res; 2004 Aug; 64(16):5570-7. PubMed ID: 15313893
[TBL] [Abstract] [Full Text] [Related]
19. Variant myst4-CBP gene fusion in a t(10;16) acute myeloid leukaemia.
Murati A; Adélaïde J; Mozziconacci MJ; Popovici C; Carbuccia N; Letessier A; Birg F; Birnbaum D; Chaffanet M
Br J Haematol; 2004 Jun; 125(5):601-4. PubMed ID: 15147375
[TBL] [Abstract] [Full Text] [Related]
20. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.
Yang XJ
Nucleic Acids Res; 2004; 32(3):959-76. PubMed ID: 14960713
[TBL] [Abstract] [Full Text] [Related]
[Next]
